Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with EGFR and YBX-1
Authors:
Open Access
- 7 April 2024
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 590, 216868
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81070656, 81170252, 82270717, 82170503, 81570779, 81870467, 32171116)
- National Key Research and Development Program of China (2022YFF0713005)
This publication has 32 references indexed in Scilit:
- EGFR signaling pathway as therapeutic target in human cancersSeminars in Cancer Biology, 2022
- Targeting hypoxia and hypoxia‐inducible factor‐1 in the tumor microenvironment for optimal cancer immunotherapyJournal of Cellular Physiology, 2021
- Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose tolerance and hepatic steatosisCell Metabolism, 2021
- Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancerCancer, 2019
- Colorectal adenocarcinoma‐derived EGFR mutants are oncogenic and sensitive to EGFR‐targeted monoclonal antibodies, cetuximab and panitumumabInternational Journal of Cancer, 2019
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific InhibitorCell, 2018
- Role of Hypoxia-inducible factor-1α and Survivin in colorectal carcinoma progressionInternational Journal of Colorectal Disease, 2008
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialThe Lancet, 2000
- Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory CompoundsNature, 1957